|
News
2008:
Alertis Medical ASA initiates its IscAlert™ Internal project.
The project will provide a broad extension of the product line
to internal organ monitoring. The project is partially financed
with funding from the Research Council of Norway with NOK 4.7
million and will take the new products to clinical trails in
2009 and 2010. The pre-clinical and clinical development will be
done in cooperation with the Interventional Center at
Rikshospitalet University Hospital in Oslo.
Alertis Medical ASA is a finalist in the DnBNor Innovation prize
for the health care sector.
2007:
IscAlert™ achieved market clearance for EU (CE-mark) and USA
(510(k)) for use in
peripheral muscle tissue.
Clinical study initiated at Sahlgrenska University Hospital.
2006:
First regulatory clinical study conducted at Rikshospitalet
University Hospital reported
2005:
Production of IscAlert™ is established at Memscap, Horten,
Norway, subsidiary of Memscap SARL, Grenoble France, an
experienced manufacturer of sensors for medical and aerospace
applications.
Alertis receives new public funding (IFU, SkatteFUNN) for its
collaboration with Memscap (www.memscap.com) of more than NOK 5
million.
Winner in of the NHO Oslo (Organization for Norwegian Employers)
innovation award.
2004:
Clinical proof-of-concept in muscle performed with IscAlert™
industrial prototype at Rikshospitalet, Oslo.
Alertis complete the industrial prototype development program
with WL Gore and retains all rights to product and technology.
|
